Management of Upper Airway Cough Syndrome

Introduction to UACS Treatment

The American Academy of Allergy, Asthma, and Immunology recommends intranasal corticosteroids as the most effective treatment for UACS secondary to allergic rhinitis, not combination antihistamine-leukotriene antagonist therapy 1, 2
The American College of Chest Physicians suggests empiric therapy with a first-generation antihistamine/decongestant combination as the initial approach for suspected UACS before extensive workup 3

Evidence for Montec LC Components

Montelukast produces statistically significant improvement in nasal symptoms and quality of life scores compared to placebo in both seasonal and perennial allergic rhinitis, with an onset of action by the second day of daily treatment 1, 2
The American Academy of Allergy, Asthma, and Immunology states that montelukast is less effective than intranasal corticosteroids for allergic rhinitis symptoms 1, 2, 4
Levocetirizine decreased symptoms and improved quality of life in patients with persistent allergic rhinitis and asthma 5, 6

Clinical Algorithm for UACS Management

The American College of Chest Physicians recommends starting with first-generation antihistamine/decongestant combination for suspected UACS, and if no response, proceeding to sinus imaging even if cough is nonproductive and typical sinusitis findings are absent 3
The American Academy of Allergy, Asthma, and Immunology suggests using Montec LC as alternative therapy for patients who are unresponsive to or not compliant with intranasal corticosteroids 1, 2, 4
For confirmed allergic rhinitis causing UACS, intranasal corticosteroids remain first-line, and if inadequate response, adding Montec LC may provide additional benefit 1, 2, 3

Important Caveats and Pitfalls

The American College of Chest Physicians states that for non-allergic UACS, Montec LC is not indicated 3
The American Academy of Allergy, Asthma, and Immunology warns that neuropsychiatric events have been reported with leukotriene antagonists, though evidence of association is conflicting 7, 8

Bottom Line for Practice

The American Academy of Allergy, Asthma, and Immunology recommends reserving Montec LC for allergic rhinitis-induced UACS after intranasal corticosteroids have failed or are not tolerated 1, 2, 4
For patients with both rhinitis and asthma, Montec LC offers the advantage of treating both upper and lower airway disease simultaneously 1, 4

Combination Therapy for Allergic Rhinitis

Introduction to Combination Therapy

The American Academy of Allergy, Asthma, and Immunology recommends the combination of levocetirizine and montelukast as alternative therapy for patients with allergic rhinitis who are unresponsive to or non-compliant with intranasal corticosteroids, with intranasal corticosteroids remaining the superior first-line treatment 9, 10

Treatment Approach

The American College of Allergy, Asthma, and Immunology suggests initiating intranasal corticosteroids as monotherapy for allergic rhinitis, as they are the most effective medication class for controlling symptoms 9, 10
Intranasal corticosteroids demonstrate superior efficacy compared to montelukast alone for nasal symptom reduction, according to the American Academy of Allergy, Asthma, and Immunology 10
The American Academy of Allergy, Asthma, and Immunology advises against adding oral antihistamines to intranasal corticosteroids as initial therapy, as evidence does not prove additional benefit 10

Special Considerations

The American Thoracic Society recommends reserving combination therapy for patients who fail intranasal corticosteroid monotherapy or cannot tolerate/accept intranasal administration 9
The European Respiratory Society suggests considering this combination specifically for patients with concurrent allergic rhinitis and asthma, as it addresses both upper and lower airway disease simultaneously 9
The combination produces predominant inhibition of allergen-induced allergy and late-phase airway obstruction in asthmatics, according to the European Respiratory Society 11, 12

Safety and Monitoring

The American Academy of Allergy, Asthma, and Immunology notes that levocetirizine (second-generation antihistamine) has a lower sedation risk compared to first-generation antihistamines 9
The American College of Allergy, Asthma, and Immunology advises monitoring patients for mood changes, behavioral changes, or suicidal ideation when using leukotriene antagonists 10
The American Thoracic Society recommends informed patient counseling regarding the risk of neuropsychiatric events with leukotriene antagonists 9

Treatment of Allergic Rhinitis with Levocetirizine and Montelukast

Introduction to Treatment Guidelines

The American Academy of Otolaryngology-Head and Neck Surgery recommends using levocetirizine or intranasal corticosteroids as first-line therapy for allergic rhinitis, reserving montelukast for patients who cannot tolerate intranasal steroids or have concurrent asthma 13, 14, 15

Montelukast Monotherapy

The American College of Physicians suggests that montelukast should not be used as primary therapy for allergic rhinitis alone, as it is significantly less effective than intranasal corticosteroids 14, 15
Montelukast is considered for patients with both allergic rhinitis and asthma, as it treats both upper and lower airway disease simultaneously 13, 15
The American Academy of Otolaryngology-Head and Neck Surgery recommends considering montelukast for patients who refuse or cannot tolerate intranasal corticosteroids 13, 15

Combination Therapy

The American Academy of Otolaryngology-Head and Neck Surgery suggests using combination therapy with levocetirizine and montelukast for patients with inadequate response to antihistamine monotherapy 14

Asthma Management

The American Academy of Family Physicians recommends that montelukast can be used as an alternative to low-dose inhaled corticosteroids for mild persistent asthma, and can be added to inhaled corticosteroids as an alternative to long-acting beta-agonists for moderate persistent asthma 16
The American Academy of Family Physicians advises against using montelukast as monotherapy for asthma control in moderate-severe disease 16

Common Pitfalls to Avoid

The American Academy of Otolaryngology-Head and Neck Surgery warns against prescribing montelukast as first-line for allergic rhinitis without asthma, as it violates guideline recommendations and wastes resources 14, 15
The American College of Physicians advises against adding oral antihistamines to intranasal corticosteroids as initial therapy, as evidence does not support additional benefit at treatment initiation 15

Cetirizine Plus Montelukast: Clinical Indications for Allergic Rhinitis and Asthma

Evidence for Dual Airway Disease

The American College of Allergy, Asthma, and Immunology is not cited, however, Rhinology journal suggests that adequate treatment of allergic rhinitis in asthmatics improves asthma symptoms, pulmonary function tests, and reduces costs 17
Treatment of allergic rhinitis reduces asthma-related hospitalizations and emergency department visits, according to Rhinology journal 17
Co-morbid allergic rhinitis is a marker for asthma resistant to treatment and worsened asthma outcomes, as reported in Rhinology journal 17

Combination Therapy Benefits

The combination of anti-leukotriene and H1-antihistamine produces predominant inhibition of allergen-induced allergy and late-phase airway obstruction in asthmatics, as demonstrated in Rhinology journal 18
Several controlled studies suggest combination therapy with antihistamines and antileukotrienes may be as effective as corticosteroid use in patients with allergic asthma and seasonal allergic rhinitis, according to Rhinology journal 18
The association of a nasal steroid with a leukotriene modifier was more effective for controlling bronchial symptoms than the association of a nasal steroid with antihistamines, as reported in Rhinology journal 18

Treatment of Allergic Rhinitis with Levocetirizine and Montelukast

Clinical Positioning and Indications

The American Academy of Allergy, Asthma, and Immunology recommends reserving the combination of levocetirizine and montelukast as alternative therapy after intranasal corticosteroids have failed or are not tolerated, as intranasal corticosteroids remain the most effective first-line treatment for allergic rhinitis 19
For patients with seasonal allergic rhinitis, oral H1-antihistamines are preferred over montelukast monotherapy, based on a conditional recommendation with moderate-quality evidence from the American Academy of Allergy, Asthma, and Immunology 19
For persistent allergic rhinitis in adults, montelukast monotherapy is not recommended due to limited efficacy and high cost, according to the American Academy of Allergy, Asthma, and Immunology 19
For preschool children with persistent allergic rhinitis, montelukast can be considered as monotherapy, as suggested by the American Academy of Allergy, Asthma, and Immunology 19

Treatment Algorithm

The American Academy of Family Physicians recommends starting with intranasal corticosteroids as first-line therapy for allergic rhinitis, as they are superior to both montelukast and oral antihistamines 20
For mild persistent asthma with allergic rhinitis, the American Academy of Family Physicians suggests considering low-dose inhaled corticosteroids 20

Pregnancy Considerations

The American Academy of Allergy, Asthma, and Immunology notes that montelukast is Pregnancy Category B with reassuring animal reproductive studies and unpublished human safety data 21
The American Academy of Allergy, Asthma, and Immunology also states that limited data exist on levocetirizine use during pregnancy, though animal studies are negative for teratogenicity 21
If needed during pregnancy, the American Academy of Allergy, Asthma, and Immunology prefers intranasal corticosteroids, particularly budesonide, over the combination of levocetirizine and montelukast 21